, cérébraux peut-être communs à ces deux affections, notamment ceux impliquant le système endocannabinoïde

, Comparaison à des patients hospitalisés au CHT-NC

, Nous avons étudié les personnes s'étant présentées au service des Urgences de l'Hôpital Gaston Bourret sur une période d'un an (année 2008) et chez qui un screening urinaire des toxiques avait été demandé

, patients ont été testés par méthode Multiscreen bmd 10® permettant de détecter la présence de méthadone, barbituriques, benzodiazépines, antidépresseurs tricycliques, cocaïne, cannabis, morphine, amphétamines, métamphétamines opiacés et ecstasy

, La consommation de kava était aussi recherchée. Dans notre étude menée en structure d'accueil des urgences, 56 patients ont été testés positifs, et parmi eux, 18 ont étés contrôlés positifs pour les cannabinoïdes urinaires

, Nous avons pu ressortir les dossiers des patients ayant été testés positifs au cannabis : Mme M. Admise pour troubles du comportement

S. Mme, Admise pour névrose hystérique. Hospitalisée 2 fois au CHS

M. , Hospitalisé pour bouffée délirante aiguë

M. , Admis deux fois aux urgences pour tentative de suicide avec intoxication éthylique

M. , Admis pour TS et intoxication éthylique

M. , Tentative de suicide au paracétamol (concentration sérique toxique : 78 mg/L)

M. , Tentative de suicide et délires paranoïdes, positif aussi pour les benzodiazépines

L. Mme, Admise pour surdosage en benzodiazépines et intoxication éthylique

M. P. , Admis pour malaises « à l'emporte-pièce ». Polytoxicomane

M. A. , Deux hospitalisations pour coma sur intoxication éthylique et cannabinique. Fume 10 joints par jour, intoxications éthyliques massives et régulières lors des fêtes et des week end

M. , Coma éthylique (éthanolémie à 4,30 g/L)

M. M. , Admis pour douleurs du pied. Présente des propos incohérents. Intoxication éthylique, consommateur de kava

L. Mme, Tentative de suicide

M. , Tentative de suicide par pendaison. Positif également pour les benzodiazépines et

C. Olievenstein, , 1987.

S. Laroche, P. Cabalion, and Y. Barguil, Typologie de la consommation de kava en Nouvelle-Calédonie, profils d'après enquêtes « à dires de buveurs », Ethnopharmacologia, vol.35, pp.19-31, 2005.

V. Lebot, P. Cabalion, . Les, and . De-vanuatu, , 1986.

S. Warter, Etude de populations exposées au kava en Nouvelle-Calédonie et à Futuna

, Contribution à la connaissance de la toxicité du kava, pp.157-60, 2003.

L. P. Davies, C. A. Drew, P. Duffield, G. A. Johnston, and D. D. Jamieson, Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain, Pharmacol Toxicol, vol.71, pp.120-126, 1992.

A. Jussofie, A. Schmiz, and C. Hiemke, Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain, Psychopharmacology, vol.116, pp.469-74, 1994.

G. Boonen and H. Haberlein, Influence of genuine kavapyrones enantiomers on the GABAa binding site, Planta Med, vol.64, pp.504-510, 1998.

G. Boonen, B. Ferger, K. Kuschinsky, and H. Haberlein, In vivo effects of the kavapyrones (+)-dihydromethysticin and (+/-)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions, Planta Med, vol.64, pp.507-517, 1998.

J. Gleitz, J. Friese, A. Beile, A. Ameri, and T. Peters, Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites, Eur J Pharmacol, vol.315, pp.89-97, 1996.

U. Seitz, A. Ameri, H. Pelzer, J. Gleitz, and T. Peters, Relaxation of evoked contractile activity of isolated guinea-pig ileum by (+/-)-kavain, Planta Med, vol.63, pp.303-309, 1997.

G. Boonen, A. Pramanik, R. Rigler, and H. Haberlein, Evidence for specific interaction between kavain and human cortical neurons monitored by fluorescence correlation spectroscopy, Planta Med, vol.66, pp.7-10, 2000.

S. S. Baum, R. Hill, and H. Rommelspacher, Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats, Prog Neuropsychopharmacol Biol Psychiatry, vol.22, pp.1105-1125, 1998.

N. Serdarevic, G. P. Eckert, and W. E. Muller, John's Wort and Kava Kava on brain neurotransmitter levels in the mouse, Pharmacopsychiatry, vol.34, pp.134-140, 2001.

U. Seitz, A. Schule, and J. Gleitz, 3H]-monoamine uptake inhibition properties of kava pyrones, Planta Med, vol.63, pp.548-557, 1997.

K. M. Garrett, G. Basmadjian, I. A. Khan, B. T. Schaneberg, and T. W. Seale, Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice, Psychopharmacology, vol.170, pp.33-41, 2003.

K. K. Smith, H. R. Dharmaratne, M. W. Feltenstein, S. L. Broom, J. T. Roach et al., Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm, Psychopharmacology, vol.155, pp.86-90, 2001.

A. Rex, E. Morgenstern, and H. Fink, Anxiolytic-like effects of kava-kava in the elevated plus maze test--a comparison with diazepam, Prog Neuropsychopharmacol Biol Psychiatry, vol.26, pp.855-60, 2002.

M. H. Pittler and E. Ernst, Efficacy of kava extract for treating anxiety: systematic review and meta-analysis, J Clin Psychopharmacol, vol.20, pp.84-93, 2000.

E. Kinzler, J. Kromer, and E. Lehmann, Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks, Arzneimittelforschung, vol.41, pp.584-592, 1991.

G. Warnecke, Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490

, Fortschr Med, vol.109, pp.119-141, 1991.

H. P. Volz and M. Kieser, Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial, Pharmacopsychiatry, vol.30, p.25, 1997.

N. N. Singh, C. Ellis, I. Sharp, and K. Eakin, A 4-week, randomized, double-blind, placebocontrolled study to investigate the effectiveness and safety of Kavatrol was conducted in a nonclinical sample with anxiety and stress, Aternative Therapies, vol.4, pp.97-105, 1998.

U. Malsch and M. Kieser, Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines, Psychopharmacology, vol.157, pp.277-83

R. J. Boerner, H. Sommer, W. Berger, U. Kuhn, U. Schmidt et al., Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients, Phytomedicine, vol.10, pp.38-49, 2003.

T. F. Munte, H. J. Heinze, M. Matzke, and J. Steitz, Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task, Neuropsychobiology, vol.27, pp.46-53, 1993.

K. W. Herberg, Effect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters, Blutalkohol, vol.30, pp.96-105, 1993.

H. J. Heinze, T. F. Munthe, J. Steitz, and M. Matzke, Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials, Pharmacopsychiatry, vol.27, pp.224-254, 1994.

B. Gessner and P. Cnota, Kava extract have positive effects on neurophysiologic and neuropsychologic responses, Z Phytother, vol.15, pp.30-37, 1994.

K. W. Herberg and U. Winter, 2nd international Congress on Phytomedecine Munich, pp.11-14, 1996.

S. Mills and K. Bone, Principles and practice of Phytotherapy, Materia Medica, pp.456-64, 2000.

D. D. Jamieson and P. H. Duffield, Positive interaction of ethanol and kava resin in mice, Clin Exp Pharmacol Physiol, vol.17, pp.509-523, 1990.

R. Kretzschmar, H. J. Meyer, H. J. Teschendorf, and B. Zollner,

, Arch Int Pharmacodyn Ther, vol.182, pp.251-68, 1969.

H. J. Meyer and J. Meyer-burg,

, Arch Int Pharmacodyn Ther, vol.148, pp.97-110, 1964.

C. Backhauss and J. Krieglstein, Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents, Eur J Pharmacol, vol.215, pp.265-274, 1992.

Y. Barguil, C. Sebat, P. Cabalion, and A. Muller, Intérêt potentiel du kava dans le traitement de douleur chronique, Douleur, vol.3, pp.18-24, 2002.

H. J. Meyer and H. V. May, Local anesthetic properties of natural kava pyrones, Klin Woch, 1964.

A. M. Duffield, D. D. Jamieson, R. O. Lidgard, P. H. Duffield, and D. J. Bourne, Identification of some human urinary metabolites of the intoxicating beverage kava, J Chromatogr, vol.475, pp.273-81, 1989.

H. B. Martin, M. Mccallum, W. D. Stofer, and M. R. Eichinger, Kavain attenuates vascular contractility through inhibition of calcium channels, Planta Med, vol.68, pp.784-793, 2002.

J. Gleitz, A. Beile, P. Wilkens, A. Ameri, and T. Peters, Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets, Planta Med, vol.63, pp.27-30, 1997.

D. Wu, L. Yu, M. G. Nair, D. L. Dewitt, and R. S. Ramsewak, Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots, Phytomedicine, vol.9, pp.41-48, 2002.

D. Wu, M. G. Nair, and D. L. Dewitt, Novel compounds from Piper methysticum Forst (Kava Kava) roots and their effect on cyclooxygenase enzyme, J Agric Food Chem, vol.50, pp.701-706, 2002.

A. Mandeau, Le kava, effets d'une consommation chronique sur les paramètres biologiques, 2000.

S. A. Norton, P. Ruze, and . Kava, J Am Acad Dermatol, vol.31, pp.89-97, 1994.

P. Ruze, Kava-induced dermopathy: a niacin deficiency, Lancet, vol.335, pp.1442-1447, 1990.

J. D. Mathews, M. D. Riley, L. Fejo, E. Munoz, N. R. Milns et al., Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community, Med J Aust, vol.148, pp.548-55, 1988.

L. Schelosky, C. Raffauf, K. Jendroska, and W. Poewe, Kava and dopamine antagonism, J Neurol Neurosurg Psychiatry, vol.58, pp.639-679, 1995.

M. Noldner and S. S. Chatterjee, Inhibition of haloperidol-induced catalepsy in rats by root extracts from Piper methysticum F, Phytomedicine, vol.6, pp.285-291, 1999.

E. Meseguer, R. Taboada, V. Sanchez, M. A. Mena, V. Campos et al., Lifethreatening parkinsonism induced by kava-kava, Mov Disord, vol.17, pp.195-201, 2002.

S. Cairney, P. Maruff, A. R. Clough, C. A. Currie, J. Currie et al., Saccade and cognitive impairment associated with kava intoxication, Hum Psychopharmacol, vol.18, pp.525-558, 2003.

P. K. Spillane, D. A. Fisher, and B. J. Currie, Neurological manifestations of kava intoxication, Med J Aust, vol.167, pp.172-175, 1997.

S. Cairney, A. R. Clough, P. Maruff, C. A. Currie, B. J. Currie et al., Saccade and cognitive function in chronic kava users, Neuropsychopharmacology, vol.28, pp.389-96, 2003.

I. Sibon, E. Rosier, and J. M. Orgogozo, Rev Neurol, vol.158, pp.1205-1211, 2002.

L. F. Garner and J. D. Klinger, Some visual effects caused by the beverage kava, J Ethnopharmacol, vol.13, pp.307-318, 1985.

F. Tarbah, H. Mahler, B. Kardel, W. Weinmann, D. Hafner et al., Kinetics of kavain and its metabolites after oral application, J Chromatogr B, vol.789, pp.115-145, 2003.

Y. Barguil, Communications personnelles sur les effets des extraits de kava

W. Homsy, Contribution de la muqueuse intestinale au métabolisme présystémique du diltiazem chez le lapin et chez l'homme, Canada, 1998.

A. K. Rasmussen, R. R. Scheline, E. Solheim, and R. Hansel, Metabolism of some kava pyrones in the rat, Xenobiotica, vol.9, pp.1-16, 1979.

B. M. Johnson, S. X. Qiu, S. Zhang, F. Zhang, J. E. Burdette et al., Identification of novel electrophilic metabolites of piper methysticum Forst (Kava), Chem Res Toxicol, vol.16, p.62, 2003.

S. Russmann, Y. Barguil, P. Cabalion, M. Kritsanida, D. Duhet et al.,

, Hepatotoxicity and enzyme induction related to aqueous extracts from kava root (piper methysticum) in New Caledonia : three cases of acute hepatitis, study of 28 heavy kava drinkers and animal studies, Pharmacoepidemiol Drug Saf, vol.11, p.22, 2002.

J. Hoelz, W. Juretzec, G. Scheinder, S. Biskup, and E. Kava-kava-rizhoma, Handbuch der pharmazeutischen Praxis, vol.6, pp.201-221, 1994.

. Sorrentino, Toxicology report, Kavapyron complex. Dep. Exp. Pharmacology, 1990.

V. Schulz and R. Hänsel, Kava-kava as an anxiolytic agent, Rational Phytotherapy, pp.78-87, 1999.

Y. N. Singh and A. K. Devkota, Aqueous kava extracts do not affect liver function tests in rats, Planta Med, vol.69, pp.496-505, 2003.

S. Hsu, M. Lin, and C. Chou, Toxicologic studies of dehydro-5,6-kawain and 5,6 dehydrokawain, Planta Med, vol.60, pp.88-90, 1994.

R. Teschke, W. Gaus, and D. Loew, Kava extracts: safety and risks including rare hepatotoxicity, Phytomedicine, vol.10, pp.440-446, 2003.

F. Stickel, H. M. Baumuller, K. Seitz, D. Vasilakis, G. Seitz et al., Hepatitis induced by Kava (Piper methysticum rhizoma), J Hepatol, vol.39, pp.62-69, 2003.

S. Russmann, Y. Barguil, P. Cabalion, M. Kritsanida, D. Duhet et al., Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia, Eur J Gastroen Hepat, vol.15, pp.1033-1039, 2003.

J. Schulze, W. Raasch, and C. P. Siegers, Toxicity of kava pyrones, drug safety and precautions--a case study, Phytomedicine, vol.10, pp.68-73, 2003.

C. L. Humberston, J. Akhtar, and E. P. Krenzelok, Acute hepatitis induced by kava kava, J Toxicol Clin Toxicol, vol.41, pp.109-122, 2003.

P. J. Gow, N. J. Connelly, R. L. Hill, P. Crowley, and P. W. Angus, Fatal fulminant hepatic failure induced by a natural therapy containing kava, Med J Aust, vol.178, pp.442-445, 2003.

, Hepatic toxicity possibly associated with kava-containing products-United States, CDC-MMWR, vol.51, pp.1065-1072, 1999.

Y. Barguil, A. Mandeau, B. Genelle, T. Dericke, A. Vara et al., Kava and gamma-glutamyltransferase increase: hepatic enzymatic induction or liver function alteration, Brit Med J eletters, 2001.

J. V. Campo, J. Mcnabb, J. M. Perel, G. V. Mazariegos, S. L. Hasegawa et al., Kava-induced fulminant hepatic failure, J Am Acad Child Adolesc Psychiatry, vol.41, pp.631-633, 2002.

M. Kraft, T. W. Spahn, J. Menzel, N. Senninger, K. H. Dietl et al.,

, Dtsch Med Wochenschr, vol.126, pp.970-972, 2001.

A. Mandeau, Y. Barguil, P. Cabalion, and D. Duhet, Effets d'une consommation chronique de kava : étude réalisée chez 19 buveurs en Nouvelle-Calédonie, Ann Toxicol Anal, vol.13, p.145, 2001.

Y. Barguil, M. Kritsanida, P. Cabalion, D. Duhet, A. Mandeau et al., Piper methysticum Forst. f.) side effects and toxicity : study of 28 heavy kava drinkers and 3 cases of acute hepatitis in occasional kava drinkers in New Caledonia, Ann Toxicol Anal, p.82, 2002.

Y. Barguil, F. Tarbah, A. Shasheen, D. Duhet, E. Choblet et al., Thirteen forensic cases related to kava consumption in New Caledonia, p.83, 2002.

Y. Barguil, S. Mermond, P. Kintz, M. Villain, E. Choblet et al., L'abus de Daturas et de kava en Nouvelle-Calédonie : une pratique inquiétante, Ann Toxicol Anal, vol.18, pp.33-43, 2006.

Y. Barguil, S. Warter, P. Cabalion, E. Choblet, and D. Duhet, Effets secondaires non psychotropes d'une consommation chronique de kava : un mécanisme commun ? Communication Affichée. Assises de la Recherche Française dans le Pacifique, p.85, 2004.

S. Russman, Y. Barguil, M. Wenk, R. Theurillat, P. Cabalion et al., Traditional aqueous kava extracts inhibit CYP4501A2 in humans, J Clin Pharm Ther, vol.75, p.83, 2004.

S. Russmann, Y. Barguil, M. Wenk, P. Cabalion, E. Choblet et al., Traditional aqueous kava extracts inhibit cytochrome P4501A2 in humans -protective effect against environmental carcinogens, J Clin Pharm Ther, vol.77, pp.453-454, 2005.

Y. Barguil, P. Cabalion, F. Tarbah, S. Russmann, D. Duhet et al., Existe-t-il une toxicité liée à la consommation de kava ? Question de santé publique, 2004.

M. Goldberg, P. Goldberg, C. Salomon, C. Hamelin, F. Haramburu et al.,

, Enquête épidémiologique sur la toxicité du kava et hépatotoxicité en Nouvelle-Calédonie. Etude de faisabilité. Rapport Inserm-IRD, 2006.

Y. Barguil, Le kava est-il responsable de dépendance ?, Bulletin Médical Calédonien & Polynésien, vol.26, p.12, 2002.

Y. Barguil, Le kava, l'avis du biologiste : un produit psychotrope non réglementé en Nouvelle-Calédonie. Communication orale, Congrès Alcoologie du Pacifique, vol.43, p.27, 2005.

Y. Barguil, F. Tarbah, E. Choblet, J. Y. Charlot, W. Weinmann et al., Pacific sedative beverage-kava-used as a drug of abuse : six recent case-reports, 2003.

F. Tarbah, Y. Barguil, W. Weinmann, C. A. Müller, D. Duhet et al., Death after consumption of kava beverage in combination with alcohol and cannabis, Communication orale GTFCh, 2003.

Y. Barguil, A. Mandeau, J. Collignon, K. Beata, and D. Duhet, Identification de kavalactones dans le sang, la salive et l'urine par CLHP/BD, approche cinétique et application à la toxicologie clinique et médicolégale, Ann Toxicol Anal, vol.13, p.139, 2001.

F. Tarbah, Y. Barguil, C. A. Mueller, A. Rickert, D. Duhet et al., Hair analysis for kavalactones and their metabolites after oral consumption of kava beverage using HPLC-DAD, Communication Orale GTFCh, 2005.

Y. Barguil, D. Duhet, and E. Choblet, Valorisation d'une plante traditionnelle océanienne Exemple du kava (Piper methysticum F.) : problèmes et perspectives, Communication Affichée UNESCO « Biodiversité Science et Gouvernance, 2005.

Y. Barguil, P. Cabalion, D. Duhet, C. Isnard, E. Choblet et al.,

, Valorisation d'une plante traditionnelle océanienne, Exemple du Kava (Piper methysticum Forst f.) : questions et perspectives. 5 ème Congrès du CIPAM, 2009.

Y. Barguil, F. Tarbah, E. Choblet, J. Y. Charlot, W. Weinmann et al.,

, Six cas d'abus de kava en Nouvelle-Calédonie. Communication Orale, Réunion AMNC / SFTA, 2003.

P. A. Whitton, A. Lau, A. Salisbury, J. Whitehouse, and C. S. Evans, Kava lactones and the kavakava controversy, Phytochemistry, vol.64, pp.673-682, 2003.

S. Fu, E. Korkmaz, F. Braet, Q. Ngo, and I. Ramzam, Influence of kavain on hepatic ultrastructures, WJG, vol.14, pp.541-546, 2008.

Y. Barguil, D. Duhet, E. Choblet, P. Cabalion, E. Hnawia et al., Lettre à la rédaction en réponse à, WJG, vol.14, pp.541-546, 2008.

Y. Barguil, F. Tarbah, M. Milkusky, C. Müller, D. Duhet et al., Oral bolus kinetic study of plasma kavalactones (KL) using a chronic kava consumer model. Communication Affichée, Assises de la Recherche Française dans le Pacifique, p.102, 2004.

Y. Barguil, P. Cabalion, M. Kritsanida, and D. Duhet, Recent research into the toxicology of Pacific medicinal plants. Pacific Herbs Business Forum, p.103, 2002.

P. Cabalion, Y. Barguil, D. Duhet, A. Mandeau, S. Warter et al., Kava in modern therapeutic uses: to a better evaluation of the benefit/risk relation. Researches in New Caledonia and Futuna, Curares, vol.26, pp.245-62, 2003.

Y. Barguil, F. Tarbah, A. Shaheen, D. Duhet, E. Choblet et al., Thirteen forensic cases related to kava consumption in New Caledonia, Communication Orale, Congrès TIAFT 2005 Séoul 105, 2002.

Y. Barguil, P. Cabalion, T. Guillaudeux, C. Isnard, E. Choblet et al.,

, Exemple du kava (Piper methysticum Forst f.) : questions, éléments de réponses et perspectives, Ethnopharmacologia, vol.45, pp.27-34, 2010.

R. E. Schultes and A. Hofmann, Plants of the Gods: Origins of Hallucinogenic Use, 1979.

M. Tabary, Consommation de cannabis en Nouvelle Calédonie : état des lieux en, 2008.

J. Bruneton and . Pharmacognosie, Phytochimie, Plantes médicinales. Paris, 3 ème Edition, pp.371-379, 1999.

G. Fournier, C. Richez-dumanois, J. Duvezin, J. P. Mathieu, and M. Paris, Identification of a new chemotype in Cannabis Sativa : Cannabigerol-dominant plant, biogenetic and agronomic prospect, Planta med, vol.53, pp.27-280, 1987.

, Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants

A. Labrousse and L. Romero, Rapport sur la situation du cannabis dans le RIF marocain, p.24, 2001.

. Moreau-j-de-tours, Du haschisch et de l'aliénation mentale. Etudes psychologiques, 1845.

J. P. Goullé, E. Saussereau, and C. Lacroix, Pharmacocinétique du ?-9-THC, Ann Pharm Fr, vol.66, pp.234-244, 2008.

, Cannabinoides et système nerveux central. 15, Expertise collective INSERM

. Cannabis, Paris : INSERM, pp.298-310, 2001.

, Système endocannabinoides et cannabinoides exogènes. 14, Expertise collective INSERM. Cannabis, quels effets sur le comportement et la santé ? INSERM, pp.285-296, 2001.

L. Venance, R. Maldonado, and O. Manzoni, Le système endocannabinoïde central, Med Sci, vol.20, pp.45-53, 2004.

H. B. Bradshaw and J. M. Walker, The expanding field of cannabimimetic and related lipid mediators, Br J Pharmacol, vol.144, pp.459-65, 2005.

S. Vandevoorde and D. Lambert, Gros plan sur les endocannabinoïdes, de nouveaux agents thérapeutiques, Chim Nouv, vol.22, pp.102-105, 2004.

B. D. Gupta, C. B. Jani, and P. H. Shah, Fatal « Bhang » poisoning, Med Sci law, vol.41, pp.349-352, 2001.

A. Aryana and M. A. Williams, Marijuana as a trigger of cardiovascular events: speculation or scientific certainty?, Int J Cardiol, vol.118, pp.141-144, 2007.

R. J. Mathew, W. H. Wilson, and R. Davis, Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics, Pharmacol Biochem Behav, vol.75, pp.309-327, 2003.

, Manuel diagnostique et statistique des troubles mentaux, 1996.

F. M. Leweke, A. Giuffrida, U. Wursted, H. M. Emrich, and D. Piomelli, Elevated endogenous cannabinoids in schizophrenia, Neuro report, vol.10, pp.1665-1674, 1999.

R. J. Mathew, W. H. Wilson, D. Humpfreys, J. V. Lowe, and K. E. Weithe, Depersonalization after marijuana smoking, Biol Psychiatry, vol.33, pp.431-441, 1993.

C. D. D'souza, A. Belger, W. Ali-saab, A. S. Gil, R. Larvery et al., Dose-response of THC effects in schizophrenics and healthy controls, Biol Psychiatry, vol.43, p.22, 1998.

N. Solowij, P. T. Michie, and A. M. Fox, Effects of long-termcannabis use on selective attention: an event-related potential study, Pharma Biochem Behav, vol.40, pp.683-688, 1991.

A. Johns, Psychiatrics effects of cannabis, Brit j psychiat, vol.178, pp.116-122, 2001.

X. Laqueille, Troubles psychiatriques liés, Rev Prat, vol.55, pp.30-34, 2005.

L. E. Hollister, Health aspects of cannabis, Pharmacol Rev, vol.38, pp.1-20, 1986.

L. Bachs and H. Morland, Acute cardiovascular fatalities following cannabis use, Forensic Sci Int, vol.124, pp.200-203, 2001.

V. Culic, Acute risk factors for myocardial infarction, Int J Cardiol, vol.117, pp.260-269, 2007.

M. A. Mittleman, R. A. Lewis, M. Maclure, J. B. Sherwood, and J. E. Muller, Triggering myocardial infarction by marijuana, Circulation, vol.103, pp.2805-2809, 2001.

N. Rodondi, M. J. Pletcher, K. Liu, S. B. Hulley, and S. Sidney, Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA Study), Am J Cardiol, vol.98, pp.478-484, 2006.

R. I. Hernig, W. E. Better, K. Tate, and J. L. Cadet, Marijuana abusers are at increased risk for stroke. Preliminary evidence from cerebrovascular perfusion data, Ann NY Acad Sci, vol.939, pp.413-415, 2001.

P. Disdier, B. Granel, and J. Serratrice, Cannabis arteritis revisited-ten new case reports, Angiology, vol.52, pp.1-5, 2001.

I. Peyrot, A. M. Garsaud, I. Saint-cyr, O. Quitman, B. Sanchez et al., Cannabis arteritis: a new case report and a review of literature, J Eur Acad Dermatol Venereol, vol.21, pp.388-391, 2007.

T. C. Wu, D. P. Tashkin, B. Djahed, and J. E. Rose, Pulmonary hazards of smoking marijuana as compared with tobacco, N Engl J Med, vol.318, pp.347-351, 1988.

P. Matthias, D. P. Tashkin, J. A. Marques-magallanes, J. N. Wilkins, and M. S. Simmons, Effects of varying marijuana potency on deposition of tar and delta9-THC in the lung during smoking, Pharmacol Biochem Behav, vol.58, pp.1145-1150, 1997.

S. E. Fligiel, M. D. Roth, E. C. Kleerup, S. H. Barsky, M. S. Simmons et al.,

, Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco, Chest, vol.112, pp.319-326, 1997.

S. H. Barsky, M. D. Roth, E. C. Kleerup, M. Simmons, and D. P. Tashkin, Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco, J Natl Cancer Inst, vol.90, pp.1198-1205, 1998.

Z. F. Zhang, H. Morgenstern, and M. R. Spitz, Marijuana use and increased risk of squamous cell carcinoma of the head and neck, Cancer Epidem Biomar, vol.8, pp.1071-1078, 1999.

J. Berthiller, K. Straif, M. Boniol, N. Voirin, V. Benhaim-luzon et al., Cannabis use and risk of lung cancer in men: a pooled analysis of three studies in Maghreb, J Thorac Oncol, vol.3, pp.1371-1373, 2008.

A. J. Sasco, R. M. Merrill, D. I. Benhaim-luzon, V. Carriot, F. Cann et al., A casecontrol study of lung cancer in Casablanca, Cancer Cause Control, vol.13, pp.609-616, 2002.

N. Voirin, J. Berthiller, V. Benhaim-luzon, M. Boniol, K. Straif et al., Risk of lung cancer and past use of cannabis in Tunisia, J Thorac Oncol, vol.1, pp.577-579, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00428043

P. Donald, Marijuana and upper aerodigestive tract malignancy in young patients, Advances in the Biosciences, vol.80, pp.39-54, 1991.

M. Hashibe, H. Morgenstern, and Y. Cui, Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study, Cancer Epidem Biomar, vol.15, pp.1829-1834, 2006.

J. A. Chacko, J. G. Heiner, W. Siu, M. Macy, and M. K. Terris, Association between marijuana use and transitional cell carcinoma, Urology, vol.67, pp.100-104, 2006.

E. A. Holly, C. Lele, P. M. Bracci, and M. S. Mcgrath, Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California, Am J Epidemiol, vol.150, pp.375-389, 1999.

S. Sidney, C. P. Quesenberry, G. D. Friedman, and I. S. Tekawa, Marijuana use and cancer incidence (California, United States), Cancer Cause Control, vol.8, pp.722-728, 1997.

J. T. Efird, G. D. Friedman, S. Sidney, A. Klatsky, L. A. Habel et al., The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: cigarette smoking and other lifestyle behaviors, J Neuro-oncol, vol.68, pp.57-69, 2004.

B. A. Moore, Respiratory effects of marijuana and tobacco use in a US Sample, JGIM, vol.20, pp.1-5, 2004.

J. M. Tetrault, K. Crothers, B. A. Moore, R. Mehra, J. Concato et al., Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review, Arch Intern Med, vol.167, pp.221-228, 2007.

, Sasco A Cannabis et risques somatiques. 10. In : Costes JM. Cannabis, données essentielles. OFDT Paris, p.91, 2007.

D. I. Abrams, J. F. Hilton, and R. J. Leiser, Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial, Ann Intern Med, vol.139, pp.258-66, 2003.

R. A. Coates, V. T. Farewell, J. Raboud, S. E. Read, D. K. Macfadden et al., Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease, Am J Epidemiol, vol.132, pp.717-722, 1990.

C. T. Bautista, J. L. Sanchez, S. M. Montano, A. Laguna-torres, L. Suarez et al., Seroprevalence of and risk factors for HIV-1 infection among female commercial sex workers in South America, Sex Transm Infec, vol.82, pp.311-316, 2006.

H. Friedman, S. Pross, and T. W. Klein, Addictive drugs and their relationship with infectious diseases, FEMS Immunol Med Mic, vol.47, pp.330-342, 2006.

W. J. Munckhof, A. Konstantinos, M. Wamsley, M. Mortlock, and C. Gilpin, A cluster of tuberculosis associated with use of a marijuana water pipe, Int J Tuberc Lung D, vol.7, pp.860-865, 2003.

D. N. Taylor, I. K. Wachsmuth, Y. H. Shangkuan, E. V. Schmidt, T. J. Barret et al., Salmonellosis associated with marijuana: a multistate outbreak traced by plasmid fingerprinting, New Engl J Med, vol.306, pp.1249-1253, 1982.

C. Hezode, F. Roudot-thoraval, S. Nguyen, P. Grenard, B. Julien et al., Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C, Hepatology, vol.42, pp.63-71, 2005.

M. Mallaret, &. Dal, D. Bo-rohrer, and M. Demattéis, Effets somatiques liés à la consommation de cannabis, Reynaud M. Traité d'addictologie. Paris : Flammarion Médecine-Sciences, vol.78, p.505, 2006.

W. C. Hembree, G. G. Nahas, P. Zeidenberg, and H. Huang, Changes in human spermatozoa associated with high dose marijuana smoking, Nahas GG, Paron M. Marihuana: biological effects, pp.429-439, 1980.

L. B. Whan, M. C. West, N. Mcclure, and S. E. Lewis, Effects of delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human sperm function in vitro, Fertil Steril, vol.85, pp.653-660, 2006.

H. S. Klonoff-cohen, L. Natarajan, and R. V. Chen, A prospective study of the effects of female and male marijuana use on in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) outcomes, Am J Obstet Gynecol, vol.194, pp.369-376, 2006.

C. Davitian, M. Uzan, A. Tigaizin, G. Ducarme, H. Dauphin et al., Maternal cannabis use and intra-uterine growth restriction, Gynecol Obstet Fertil, vol.34, pp.632-637, 2006.

D. A. Frank, H. Bauchner, S. Parker, A. M. Hubert, and K. Kyei-aboagye, Neonatal body proportionality and body composition after in utero exposure to cocaine and marijuana, J Pediatr, vol.117, pp.622-626, 1990.

B. Zuckerman, D. A. Frank, R. Hingson, H. Amaro, S. M. Levenson et al., Effects of maternal marijuana and cocaine use on fetal growth, N Eng J Med, vol.320, pp.762-768, 1989.

S. Linn, S. C. Schoenbaum, R. R. Monson, R. Rosner, P. C. Stubblefield et al., The association of marijuana use outcome of pregnancy, Am J Public Health, vol.73, pp.1161-1164, 1983.

N. Day, U. Sambamoorthi, P. Taylor, G. Richardson, N. Robles et al., Prenatal marijuana use and neonatal outcome Neurotoxicol, Teratology, vol.13, pp.329-334, 1991.

N. L. Day, C. M. Cottreau, and G. A. Richardson, The epidemiology of alcohol, marijuana and cocaine use among women of childbearing age and pregnant women, Clin Obste Gyneco, vol.36, pp.232-245, 1993.

E. K. Steinberg, C. Ferenez, and C. A. Loffredo, Infant with single ventricle: a population-based epidemiological study, Teratology, vol.65, pp.106-115, 2002.

L. J. Williams, A. Correa, and S. Rasmussen, Maternal lifestyle factors and risk for ventricular septal defects, Teratology, vol.70, pp.59-64, 2004.

C. P. Torfs, E. M. Velie, F. W. Oechsli, T. F. Bateston, and C. J. Curry, A population-based study of gastroschisis: dermographic, pregnancy, and lifestyle risk factor, Teratology, vol.50, pp.44-53, 1994.

R. K. Scrag, E. A. Mitchell, R. P. Ford, J. M. Thompson, B. J. Taylor et al., Maternal cannabis use in the sudden death syndrom, Acta paediatr, vol.90, pp.57-60, 2001.

H. Klonoff-cohen and P. Lam-kruglick, Maternal and paternal recreational drug use and sudden infant death syndrom, Arch Pediatr Adolesc Med, vol.155, pp.765-770, 2001.

L. Karila, J. Vignau, C. Alter, and M. Reynaud, Altération cognitive liée à la consommation aigue et chronique de cannabis, Rev Prat, vol.55, pp.23-26, 2005.

P. Deniker, H. Colonna, and H. Loo, Pharmacopsychose et syndrome déficitaire, Evol Psychiatr, vol.214, p.283, 1973.

D. Richard and J. L. Senon, Le cannabis, revue bibliographique générale, Revue toxibase, vol.1, pp.1-25, 1995.

B. Defer, Les troubles mentaux provoqués par l'usage prolongé du cannabis, Textes et Documents, Colloque scientifique international, Les drogues illicites. Académie nationale de médecine 8-9, pp.89-92, 1992.

J. Macleod, R. Oakes, A. Copello, I. Crome, M. Egger et al., Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies, Lancet, vol.363, pp.1579-1588, 2004.

I. Rapport, Cannabis, quels effets sur la santé ? Chapitre 6 consommations de cannabis et troubles psychotiques, pp.117-136, 2004.

S. Potvin, E. Stip, and J. Y. Roy, Schizophrénie et cannabinoïdes : données cliniques, expérimentales et biologiques. Drogue, santé et société, vol.2, pp.1-16, 2004.

M. Hambrecht and M. Hafner, Cannabis use and psychosis: A review of clinical and epidemiological evidence, Aust NZ J Psychiat, vol.34, pp.468-475, 2000.

E. G. Karam, P. F. Yabroudi, and N. M. Melhem, Comorbidity of substance abuse and other psychiatric disorders in acute general psychiatric admissions: a study from Lebanon, Compr Psychiatry, vol.220, pp.35-40, 2002.

E. J. Cone, Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol, J Anal Toxicol, vol.11, pp.89-96, 1987.

R. S. Niedbala, Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle, J Anal Toxicol, vol.29, p.83, 2005.

R. S. Niedbala, K. Kardos, S. Fritch, D. Bronsgeest, M. Cone et al., Passive cannabis smoke exposure and oral fluid testing, J Anal Toxicol, vol.28, pp.546-552, 2004.

A. Dervaux, J. P. Olie, X. Laqueille, and M. O. Krebs, Conduites addictives chez 100 sujets schizophrènes, Encéphale, vol.25, p.183, 1999.

E. Duau and A. Dervaux, Toxicomanie et schizophrénie. Séminaire de psychiatrie biologique: hôpital Sainte-Anne, vol.30, pp.93-112, 2000.

C. Morgan and V. Curran, Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis, Br J Psychiatry, vol.192, pp.306-313, 2008.

F. Liraud and H. Verdoux, Clinical and prognostic characteristics associated with addictive comorbidity in hospitalized psychiatric patients, Encéphale, vol.26, pp.16-23, 2000.

E. Van-ammers, J. D. Sellman, and R. T. Mulder, Temperament and substance abuse in schizophrenia : is there a relationship ?, J Nerv Ment Dis, vol.185, pp.283-288, 1997.

Y. Barguil, J. Y. Charlot, G. Southwell, P. Kintz, F. Baumann et al., Evaluation du risque d'apparition de comorbidités psychiatriques chez le consommateur de cannabis par la détermination du rapport des concentrations capillaires en THC et en CBD, Communication Orale, 2010.

D. C. D'souza, P. E. Macdougall, L. Ammerman, Y. Cooper, T. Wu et al., The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis, Neuropsychopharmacology, vol.29, pp.1558-72, 2004.

Y. Barguil and . Le, Faibles risques de dépendance, mais toxicité neurocomportementale importante, Bulletin Médical Calédonien & Polynésien, vol.26, pp.9-93, 2002.

Y. Barguil, V. Cirimele, J. Y. Charlot, D. Duhet, M. Villain et al., Teneurs en ?-9 tétrahydrocannabinol de la marijuana saisie en, 2004.

, Bulletin Médical Calédonien & Polynésien, 2005.

Y. Barguil, A. Guégan, J. Y. Charlot, P. Anselot, E. Choblet et al., Approche toxicologique du cannabis en Nouvelle-Calédonie : nouvelles connaissances. Com orale, La Semaine Santé et Sécurité au Travail, p.95, 2009.

Y. Barguil, E. Choblet, A. Guégan, L. Lepot, and J. Y. Charlot, Les modalités du dépistage des stupéfiants. Com orale, La Semaine Santé et Sécurité au Travail. Nouméa octobre, p.96, 2009.

Y. Barguil and E. Choblet, Alcool, cannabis et accident de la voie publique en Nouvelle-Calédonie. Com affichée, La Semaine Santé et Sécurité au Travail. Nouméa octobre, p.97, 2009.

Y. Barguil, Une situation alarmante. Communication Orale Session plénière Conseil Economique et Social de la Nouvelle-Calédonie, 2004.

E. Choblet, Y. Barguil, J. Y. Charlot, and D. Duhet, Traitement psychotrope et toxicomanie en Nouvelle-Calédonie. Communication Affichée, Assises de la Recherche Française dans le Pacifique, 2004.

, relative aux mesures sanitaires de lutte contre la toxicomanie et la répression du trafic et de l'usage des substances vénéneuses 100

N. Cambillau, Santé publique/droit pénal L'usage de cannabis : entre répression excessive et dépénalisation problématique, Médecine & Droit, vol.58, pp.3-16, 2003.

, -297 du 5 mars 2007 relative à la prévention de la délinquance 102 Loi n°2003-495 du 12 juin 2003 renforçant la lutte contre la violence routière, p.45, 2007.

L. De-la, juin 2003 rendant applicable à la Nouvelle-Calédonie la lutte contre la violence routière 103

M. A. Huestis, J. E. Henningfield, and E. J. Cone, Blood cannabinoids. II. Models for the prediction of time of majiruana exposure from plasma concentrations of Delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH), J Anal Toxicol, vol.16, pp.283-290, 1992.

F. Musshoff and M. Burkhard, Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use, Ther Drug Monit, vol.28, pp.155-162, 2006.

P. Kintz and V. Cirimele, Testing human hair for cannabis, Forensic Sci Int, vol.70, pp.175-182, 1995.

M. A. Huestis, A. Richard, E. T. Gustafson, A. Moolchan, J. A. Bames et al., Cannabinoide concentration in hair from documented cannabis user, Forensic Sci Int, vol.169, pp.129-136, 2007.

F. Pragst, Pitfalls in hair analysis resulting from variability of human hair growth and from alternative drug incorporation mechanism, Ann Toxico Annal, vol.17, p.109, 2005.

M. Uhl, Determination of cannabinoids in human hairs in Analytical and practical aspects of drug testing, 2006.

K. Röhrich and J. , Concentrations of ? 9 -tetrahydrocannabinol, cocaine and 6-monoacetylmorphine in hair of drug abusers, Int J Legal Med, vol.108, p.294, 1996.

L. Tsanaclis, Hair analysis for assessing cannabis use. Where is the cutt-off? Personal communication, 2005.

P. Kintz, M. Villain, V. Cirimele, C. Jamey, and B. Ludes, Décret n° 2003-293 du 31 mars 2003. Restitution du permis de conduire à partir d'analyses des cheveux, Ann Toxicol Anal, vol.15, pp.117-139, 2003.

Y. Barguil, Le cannabis, ses principaux cannabinoïdes et ses éléments traces : intérêt judiciaire, à propos d'une affaire criminelle en Nouvelle-Calédonie. D.U. de Médecine Légale et de Sciences Criminelles Opt Sciences criminelles, 2009.

, Etude « stupéfiants et accidents mortels de la circulation routière, 2005.

T. Jaffré, Composition chimique et conditions de l'alimentation minérale des plantes sur roches ultramafiques en, Cah ORSTOM, sér Biol, vol.XI, pp.53-63, 1976.

Y. Barguil, P. Kintz, M. Villain, B. Fogliani, V. Cirimele et al., Profils cannabinoïdes et multiélémentaires : intérêt judiciaire, Ann Toxicol Anal, vol.21, p.98, 2009.

, Carte des gites minéraux et substances utiles de Nouvelle-Calédonie

C. Bowles, DNA profiling used on cannabis plants, 2003.

G. Müller, D. Eggersgluess, and N. Raju, Heavy metal (Cd, Cu, Pb, Cr, Zn, Hg) concentrations in tobacco of commonly smoked cigarette brands purchased in Germany

A. W. Zuardi, J. Crippa, J. Hallak, F. A. Moreira, and F. S. Guimaraes, Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug, Braz J Med Biol Res, vol.39, pp.421-429, 2006.

Y. Barguil, S. Mermond, P. Kintz, M. Villain, E. Choblet et al., L'abus de Daturas et de kava en Nouvelle-Calédonie : une pratique inquiétante, Annal Toxicol Anal, vol.18, pp.33-43, 2006.

H. S. Mackee, Catalogue des plantes introduites et cultivées en Nouvelle-Calédonie, pp.130-131, 1994.

D. T. Chau, P. Rada, R. A. Kosloff, J. L. Taylor, and B. G. Hoebel, Nuccleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test, Neurosci, vol.104, pp.791-799, 2001.

E. Valjent, C. Pagès, D. Hervé, J. A. Girault, and J. Caboche, Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain, Eur Neurosci, vol.19, pp.1826-1862, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00077883

F. Guerra, Sex and drugs in the 16 th Century, Br J Addict, vol.69, pp.269-90, 1974.

J. P. Anger, M. Villain, A. Baert, and P. Kintz, Le datura : une plante oubliée de la pharmacopée mais qui semble de plus en plus plébiscitée par les jeunes, Annal Toxicol Anal, vol.16, p.166, 2004.

, Revault d'Alonnes E. Datura : remède ou poison ? Thèse d'exercice de Pharmacie, 2007.

V. Paris,

H. Arouko, M. D. Matray, C. Bragança, J. P. Mpaka, L. Chinello et al., Une autre cause d'hospitalisation des jeunes en quête de sensations fortes, Ann Med Interne, vol.154, pp.1-46, 2003.

J. Bruneton, Alcaloïdes tropaniques, Pharmacognosie. Phytochimie. Plantes médicinales, pp.805-829, 1999.

P. Kintz, M. Villain, Y. Barguil, J. Y. Charlot, and V. Cirimele, Testing for atropine and scopolamine in hair by LC-MS/MS after Datura inoxia abuse, J Anal Toxicol, vol.30, pp.454-461, 2006.

K. C. Quek and J. S. Cheah, Poisoning due to ingestion of the seeds of kechubong (Datura fastuosa) for its ganja-like effect in Singapore, J Trop Med Hyg, vol.77, p.12, 1974.

I. Schneider, Intoxication au Datura en Gironde entre 2001 et 2005 : à propos de 16 cas, 2006.

M. Tollet, Etude des cas recencés au Centre Antipoison d'Angers, Angers, vol.14, 2000.

F. Roblot, L. Montaz, M. Delcoustal, E. Bagouyriau, J. J. Chavagnat et al., Intoxication par Datura stramonium : le diagnostic est clinique, le traitement est symptomatique, Rev Méd Interne, vol.16, pp.187-190, 1995.

B. Tapie, Intoxication par le Datura : à propos de 10 cas reçus au Groupe Hospitalier Sud Réunion, 2004.